| |
|
|
|
WBR, Hotel President Wilson, Geneva, Switzerland
19 Sep 2006
Main Conference Day 1
20 September 2006
9:00-9:30 Keynote Address:
What New Generation Of Inlicensing Opportunities Will Fill Big Pharma’s Pipeline Gaps In The Next 3 Years?To invite: Lisa Ricciardi, Senior VP, Licensing & Development, Pfizer 9:30-10:00
What Is The Profile Of Today’s Most Successful Biotechs, And What Key Drivers Will Determine Tomorrow’s Winners? Confirmed: Dr Peter Heinrich, CEO, MediGene 10:00-10:30
The Roche/Amira Case Study To invite: Roche/Amira 10:30-11:00
The Bristol-Myers Squibb/Nerviano Case Study To invite: Bristol-Myers Squibb/Nerviano 11:00 Coffee 11:30-12:00
The Bayer/Onyx Case Study: Has Big Pharma Reaped The Rewards Of Its Co-Development Partnership And To What Extent Is It A Model For The Future? Confirmed: Christopher Seaton, Senior VP, Global Licensing & Business Development, Bayer 12:00-12:30 Panel Discussion & Partnering Outlook For 2007:
To What Extent Is Proof Of Concept In Humans Still A Fundamental Requirement For Attracting The Interest Of Big & Mid-Sized Pharma? Confirmed: Jules Musing, VP, Global Licensing & Business Development, Johnson & Johnson
Confirmed: Margaret Beer, Director, Scientific Liaison, Merck
Other Panellists TBC
12:30-13:00 Panel Discussion:
Are We Approaching The End Of The Blockbuster Drug Era, And If So, How Do Big Pharma Intend To Adapt Their Licensing Strategy?
|
|
|
|
|
|
|
|
Organized by:
|
|
WBR |
|
|
Invited Speakers:
|
|
Dr Roger Lloyd, Executive Director, Global Licensing, AstraZeneca
Dr Judith Hills, VP, External Science Technology & Licensing, Bristol-Myers Squibb
Dr John Shiver, Executive Director, Viral Vaccine Research, Merck
Jules Musing, VP, Global Licensing & Business Development, Johnson & Johnson
Christopher Seaton, Senior VP, Global Licensing & Business Development, Bayer
Chris Henderson, Director of Global Licensing, AstraZeneca
Doug Pon, Assistant VP, Vaccines Licensing, Wyeth
Dr Klaus Wilgenbus, Head of Corporate Division Licensing, Boehringer Ingelheim
Margaret Beer, Director, Scientific Liaison, Merck
Dr Marc Herin, Manager, Global External R&D, Europe, Eli Lilly
Jonathan Freeman, Director, Business Development Europe, Baxter Healthcare
Dr Lucienne Cicurel, Secretary General, Debiopharm
Dr Peter Heinrich, CEO, MediGene
Dr Yasuhiro Endo, CEO, Innovatis Pharma
Ulrich Dauer, CEO, 4SC
Mark Leuchtenberger, CEO, Therion Biologics
Dr Jean-Pierre Rosat, CEO, Apoxis
Michele Garufi, CEO, NicOx
Andrea Pfeifer, CEO, AC Immune
Ian Nicholson, CEO, Chroma Therapeutics
Roland Kozlowski, CEO, Lectus Therapeutics
Dr Wolfgang Klein, CFO, CureVac
Dr Steven Lee, CEO, VASTox
Meenu Chhabra, Chief Business Officer, BioXell
Dr Regina Hodits, Partner, Atlas Venture
Rainer Strohmenger, General Partner, Wellington Partners
Professor Karol Sikora, Consultant Oncologist, Imperial College School of Medicine
Angus Dalgleish, Foundation Professor of Oncology, St George’s University of London
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
None
|
|
|
|
|
|
|
|
Registration:
|
|
On line
|
|
|
E-mail:
|
|
Saddif11@wbr.co.uk
|
|
|
|
|
|
|
|
|